Description
Atorvastatin, Clopidogrel, and Aspirin Capsules combine three cardiovascular agents to provide comprehensive secondary prevention in patients at high risk of atherothrombotic events such as myocardial infarction, stroke, or unstable angina.
-
Atorvastatin is a statin that lowers LDL cholesterol and triglycerides, while modestly increasing HDL cholesterol. It also has anti-inflammatory and plaque-stabilizing effects.
-
Clopidogrel is a P2Y12 platelet aggregation inhibitor that prevents the formation of blood clots by blocking ADP receptors on platelets.
-
Aspirin is an antiplatelet agent (NSAID) that irreversibly inhibits cyclooxygenase-1 (COX-1), reducing thromboxane A2 production and preventing platelet activation.
Together, this fixed-dose combination reduces cardiovascular risk through lipid management and dual antiplatelet therapy (DAPT).
Mechanism of Action:
- Atorvastatin: Inhibits HMG-CoA reductase, lowering cholesterol synthesis.
- Clopidogrel: Inhibits ADP-mediated platelet activation and aggregation.
- Aspirin: Inhibits thromboxane A2 production via COX-1 inhibition.
This triple-action helps prevent clot formation, lower lipid levels, and reduce inflammation in the vasculature.
Indications:
- Secondary prevention of cardiovascular events (e.g., MI, stroke, PAD)
- Post-percutaneous coronary intervention (PCI) or coronary artery stenting
- Patients with established atherosclerotic cardiovascular disease (ASCVD)
- Stable or unstable angina
- Transient ischemic attacks (TIAs)
